TY - GEN
T1 - Nidogen-1 (NID1) as specific ligand in natural killer (NK) cells stimulated from advanced ovarian cancer
T2 - 5th International Symposium of Biomedical Engineering, ISBE 2020
AU - Khaerunnisa, Sanya
AU - Pangjaya, Lady Feren
AU - Mazfufah, Nuzli Fahdia
AU - Budiman, Retno Lestari
AU - Antarianto, Radiana Dhewayani
N1 - Funding Information:
Funding for this research is obtained from Dana Masyarakat (DAMAS) UI through PUTI Universitas Indonesia Research Grant 2020 contract number ND-47/UN2.F1.DEPT.1/SDM.01.01/2020 and with principal investigator Radiana Dhewayani Antarianto.
Publisher Copyright:
© 2021 Author(s).
PY - 2021/3/23
Y1 - 2021/3/23
N2 - The pathway for the introduction of NK cell into abnormal cells is mediated by the receptor-ligand interaction on the cell surface. Among all the activation receptors, NKP44 has become a unique activation receptor because it has an ITIMs signaling pathway and actively plays an important role in several functions of stimulated NK cells. A potential ligand that can specifically regulate the activity of NKP44 receptors is NID1. NID1 is a novel ligand that can initiate two different regulations on NK cells activity. In addition, NID1 also provides predictions that are compatible with the electrophoretic glycoprotein mobility that has been detected by NKp44 through SDS-PAGE and ELISA tests compared to all proteins in the microenvironment of ovarian cancer. Curently, NID1 has been proven to be able to increase the cytotoxic reaction of non-cancerous NK cells. Further research is needed for the development of ovarian cancer immunotherapy based on the receptor-ligand interactions.
AB - The pathway for the introduction of NK cell into abnormal cells is mediated by the receptor-ligand interaction on the cell surface. Among all the activation receptors, NKP44 has become a unique activation receptor because it has an ITIMs signaling pathway and actively plays an important role in several functions of stimulated NK cells. A potential ligand that can specifically regulate the activity of NKP44 receptors is NID1. NID1 is a novel ligand that can initiate two different regulations on NK cells activity. In addition, NID1 also provides predictions that are compatible with the electrophoretic glycoprotein mobility that has been detected by NKp44 through SDS-PAGE and ELISA tests compared to all proteins in the microenvironment of ovarian cancer. Curently, NID1 has been proven to be able to increase the cytotoxic reaction of non-cancerous NK cells. Further research is needed for the development of ovarian cancer immunotherapy based on the receptor-ligand interactions.
KW - immunotherapy
KW - NID1
KW - NK cell
KW - NKP44
KW - ovary cancer
UR - http://www.scopus.com/inward/record.url?scp=85103487578&partnerID=8YFLogxK
U2 - 10.1063/5.0049157
DO - 10.1063/5.0049157
M3 - Conference contribution
AN - SCOPUS:85103487578
T3 - AIP Conference Proceedings
BT - 5th Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, and Medical Devices
A2 - Lischer, Kenny
A2 - Supriadi, Sugeng
A2 - Rahman, Siti Fauziyah
A2 - Whulanza, Yudan
PB - American Institute of Physics Inc.
Y2 - 28 July 2020 through 29 July 2020
ER -
